POTASSIUM PHOSPHATES INJECTION, USP DIN 02139545
Status: Marketed
Holder: FRESENIUS KABI CANADA LTD
Molecule: POTASSIUM PHOSPHATE MONOBASIC
Available to quote
Health Canada record
| Active ingredient(s) | POTASSIUM PHOSPHATE MONOBASIC 224 MG; POTASSIUM PHOSPHATE DIBASIC 236 MG |
|---|---|
| Dosage form | Solution |
| Route | Intravenous |
| Schedule | ETHICAL |
| Class | Human |
| ATC | B05XA06 POTASSIUM PHOS INCL COMB W/0TH POT. SALTS |
| Original market date | 31-Dec-1984 |
| Current status date | 22-Dec-2015 |
| Source | Health Canada DPD |
Establishment licence of the holder
Fresenius Kabi Canada Ltd. — licence 102232, currently licensed, last inspection rating C (2025-10-01).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing POTASSIUM PHOSPHATE MONOBASIC
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 00711306 | POTASSIUM PHOSPHATE MONOBASIC INJECTION | SANDOZ CANADA INCORPORATED | Solution | POTASSIUM PHOSPHATE MONOBASIC 176 MG | Marketed |
| 00804789 | POTASSIUM PHOSPHATES | SANDOZ CANADA INCORPORATED | Liquid | POTASSIUM PHOSPHATE MONOBASIC 224 MG; POTASSIUM PHOSPHATE DIBASIC 236 MG | Marketed |
| 00351539 | POTASSIUM PHOSPHATE INJ 3MMP/ML | HOSPIRA HEALTHCARE ULC | Solution | POTASSIUM PHOSPHATE MONOBASIC 224 MG; POTASSIUM PHOSPHATE DIBASIC 236 MG | Cancelled Post Market |
| 01944878 | POTASSIUM PHOSPHATES INJ | LYPHOMED, DIVISION OF FUJISAWA CANADA INC. | Liquid | POTASSIUM PHOSPHATE MONOBASIC 224 MG; POTASSIUM PHOSPHATE DIBASIC 236 MG | Cancelled Post Market |
International API supply for POTASSIUM PHOSPHATE MONOBASIC
3 active FDA Drug Master Files.
Request a quote for POTASSIUM PHOSPHATES INJECTION, USP